Biotech News
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
Open original release
Related news
BMYBMYBristol-Myers Squibb Company2026-06-01 10:55 EST
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
BMYBMYBristol-Myers Squibb Company2026-05-08 10:59 EST
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
ARGXArgenx2026-05-08 21:20 EST
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
KRYSKrystal Biotech2026-05-18 12:00 EST
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
INBXInhibrx2026-06-15 13:15 EST
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
GSKGSK plc2026-06-12 12:00 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-17 16:00 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
COGTCogent Biosciences2026-05-28 12:00 EST
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
REPLReplimune Group2026-05-29 12:00 EST
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
PCVXVaxcyte2026-06-02 20:05 EST
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
GSK plc
GSK is a global biopharmaceutical company with meaningful exposure to vaccines, respiratory medicines, immunology, and infectious disease. The company has been reshaping its portfolio around stronger innovation and higher-growth specialty products.
Recent company news
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
GSKGSK plc2026-07-22 11:21 EST
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Stock data
- Close
- 51.98 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States